Researchers from Sichuan University and Chengdu Normal University have reported the discovery of novel G9a/GLP covalent inhibitors for the treatment of triple-negative breast cancer (TNBC).
Researchers from West China Hospital of Sichuan University presented data from a study that aimed to investigate the associations between serum cystatin C (CysC) levels and the progression and survival of patients with amyotrophic lateral sclerosis (ALS).
West China Hospital of Sichuan University has disclosed piperidine derivatives acting as μ-opioid receptor agonists and sigma non-opioid intracellular receptor 1 (SIGMAR1) antagonists.
Human dihydroorotate dehydrogenase (hDHODH) is a mitochondrial enzyme participating in de novo pyrimidine biosynthesis essential for T- and B-lymphocyte proliferation.
Novel effective antivirals against SARS-CoV-2 are needed because of the emergence of novel variants and the potential risk of SARS-CoV-2/MERS-CoV recombination. The SARS-CoV-2 main protease (Mpro) is a promising antiviral target. Mpro presents a His41-Cys145 catalytic dyad in the central part of its active site, which confers a natural advantage for developing covalent drugs.
Aryl hydrocarbon receptor (AhR) is a ligand-dependent transcription factor that maintains skin homeostasis in healthy skin and is expressed in keratinocytes, fibroblasts, mastocytes and melanocytes. In inflammatory skin disorders such as psoriasis, AhR deficit leads to marked skin inflammation, abnormal barrier function and increased cytokine release. Researchers from Sichuan University have reported the discovery and optimization of a new series of 2-thioxoimidazolidin-4-one derivatives acting as AhR agonists that led to the identification of [I] as the lead compound, which showed an EC50 value of 0.015 µM against AhR.
Researchers from Sichuan University synthesized new pyrazole amides based on the previously described NADH-ubiquinone oxidoreductase (complex I, CI) inhibitor IACS-010759. Subsequent optimization resulted in the identification of SCAL-255 and SCAL-266 as lead candidates with potent CI inhibitory activity.
Researchers at West China Hospital, Sichuan University have identified remimazolam derivatives reported to be useful for the treatment of sedation and as anesthetics.
China's National Medical Products Administration (NMPA) has given drug clinical trial approval for two new COVID-19 vaccines against the current XBB variants developed by Westvac Biopharma Co. Ltd. and West China Medical Center at Sichuan University.
